Working to deliver
your IBD study on time

As the need for clinical trials in Crohn’s disease and ulcerative colitis grows, CRO collaboration matters more than ever.

The number of IBD clinical trials initiated per year has grown tremendously over the last decade. With the increase in the duration of these trials, the number of ongoing trials continues to rise.

Deliver your next trial on time. Be ahead of the competition.

In today’s crowded IBD clinical trials landscape, surprise yourself.

You want to complete your IBD study as quickly as possible, and that’s a challenge in this highly competitive landscape. You have many questions:

  • How should you position your drug on the market?
  • How can you make your study stand out from the crowd?
  • How do you choose the right countries?
  • How do you engage investigators and patients?
  • What recruitment campaigns should you choose from?

You need a CRO that has credible answers, plenty of specific experience, and a track record of completing pivotal Phase 2 and 3 Crohn’s disease and ulcerative colitis clinical trials on or ahead of projected timelines.

PSI’s key differentiator is our ability to plan and execute complex clinical trials on time, saving our customers millions of development dollars.

PSI Enrollment Rates

Despite the competition, PSI continues to deliver higher enrollment rates than typical across the industry:

PSI recruits faster due to our relationships with more than 3,900+ IBD sites around the world.

Our studies are successful due to our long-term relationships with recruiting sites; we know the investigators on a personal level and they are motivated to work with us.

With the number and duration of IBD studies increasing over the last decade, we know your study will face competition. Our experience shows investigator and site relationships are key to navigating this challenge and we will help you achieve this.

We work with a mixture of academic centers, regional hospitals, state funded hospitals, and private GI clinics that deliver enrollment and high-quality data. By reviewing our ongoing and previous IBD studies we can identify the ideal site profile to deliver patients for your study.

We will ensure your study is prioritized at our sites.

PSI CRO targets sites that meet the following criteria:

  • Proven history of meeting or exceeding enrollment goals.
  • Equipped to perform flexible sigmoidoscopy/ colonoscopy assessments, EKGs & MRIs where required.
  • High volume of IBD patient referrals with a large database of target patients.
  • Limited number of competing trials

Ready to Learn More about PSI CRO?

Interested in a proposal? Have a question? We're happy to get in touch with you as soon as possible.

Contact Us

Our IBD Sites Open Around the World

PSI’s Recent IBD Achievements

Successfully delivered dozens of phase II and III IBD studies

A track-record of successful FDA inspections and drug approvals

Built and nurtured a database of 2,500+ sites across the globe

Achieved enrollment rates 20% higher than the industry average

Worked with S1P1 receptor modulators, JAK inhibitors, other small molecules; biologics; 5-ASA; microbiome therapies

Coached 30 project managers with GI focus

Read more about IBD clinical trials

“One of the most seamless partnerships between a sponsor and a CRO that I have ever seen.”

VP Global Clinical Operations

The PSI Advantage

For the sixth year in a row, PSI CRO has been named a CRO Leadership Award winner in the categories of Expertise, Quality, and Reliability in the Overall (combined Big and Small pharma) respondent group. The CRO Leadership Awards are presented by Life Sciences Leader and Clinical Leader based on research conducted by ISR Reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.

Therapeutic areas

Inflammatory Bowel Diseases (IBD)

Crohns’ Disease, Ulcerative Colitis and other IBDs.


Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer and other Oncology indications.


Multiple Myeloma, Lymphomas, Leukemias and other oncohematological indications.

Infectious Diseases

Antimicrobial and Antifungal infections and other ID.

Multiple Sclerosis

Multiple Sclerosis, Spasticity and other neurological indications.

Rare Diseases

Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).